New-Onset of Crohn’s Disease Is Associated with Antistreptolysin O Positive Titers

References

• Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24(sup170):2–6. doi:10.3109/00365528909091339
   Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s Disease. Part 1: diagnosis and medical management. J Crohns Colitis. 2016;11(1):3–25. doi:10.1093/ecco-jcc/jjw168
   Web of Science ®Google Scholar
• Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn’s disease. F1000 Prime Rep. 2015;7:44. doi:10.12703/P7-44
   PubMedGoogle Scholar
• Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ. 1988;297(6656):1105–1106. doi:10.1136/bmj.297.6656.1105
   PubMed Web of Science ®Google Scholar
• Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101(10):2410–2422. doi:10.1111/j.1572-0241.2006.00840.x
   PubMed Web of Science ®Google Scholar
• Joossens S, Colombel JF, Landers C, et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut. 2006;55(11):1667–1669. doi:10.1136/gut.2005.089623
   PubMed Web of Science ®Google Scholar
• Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56(10):1394–1403. doi:10.1136/gut.2006.108043
   PubMed Web of Science ®Google Scholar
• Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113(9):1296–1306. doi:10.1172/JCI200420295
   PubMed Web of Science ®Google Scholar
• Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of Group A Streptococcus. Clin Microbiol Rev. 2014;27(2):264–301.
   PubMed Web of Science ®Google Scholar
• Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32(8):979–983. doi:10.1093/sleep/32.8.979
   PubMed Web of Science ®Google Scholar
• Sun L, Wu R, Xue Q, Wang F, Lu P. Risk factors of uveitis in ankylosing spondylitis: an observational study. Medicine. 2016;95(28):e4233. doi:10.1097/MD.0000000000004233
   Web of Science ®Google Scholar
• Al-Sheyyab M, Batieha A, El-Shanti H, Daoud A. Henoch-Schonlein purpura and streptococcal infection: a prospective case-control study. Ann Trop Paediatr. 1999;19(3):253–255. doi:10.1080/02724939992329
   PubMed Web of Science ®Google Scholar
• Sato H, Ishikawa H. Unspecific increase of antistreptolysin-O titer in acute guttate psoriasis. J Dermatol. 1977;4(5):187–191. doi:10.1111/j.1346-8138.1977.tb01036.x
   Google Scholar
• Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;128(1):39–42. doi:10.1001/archderm.1992.01680110049004
   PubMedGoogle Scholar
• Gupta R, Prakash K, Kapoor AK. Subclinical group A streptococcal throat infection in school children. Indian Pediatr. 1992;29:1491–1494.
   Google Scholar
• Hammad T, Staros EB. Antistreptolysin O Titer [Online, 29 June 2019]; 2014. Emedicine.medscape.
   Google Scholar
• Rantz LA, Randall E, Rantz HH, Antistreptolysin O. A study of this antibody in health and in hemolytic Streptococcus respiratory disease in man. Am J Med. 1948;5(1):3–23. doi:10.1016/0002-9343(48)90003-5
   Web of Science ®Google Scholar
• Ben-Chetrit E, Moses AE, Agmon-Levin N, Block C, Ben-Chetrit E. Serum levels of anti-streptolysin O antibodies: their role in evaluating rheumatic diseases. Int J Rheum Dis. 2012;15(1):78–85. doi:10.1111/j.1756-185X.2011.01668.x
   Web of Science ®Google Scholar
• Geerts I, De Vos N, Frans J, Mewis A. The clinical-diagnostic role of Antistreptolysin O antibodies. Acta Clin Belg. 2011;66(6):410–415. doi:10.2143/ACB.66.6.2062604
   Web of Science ®Google Scholar
• Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer WR, Coutu JA. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn’s disease. J Clin Microbiol. 1984;20(5):966–971. doi:10.1128/JCM.20.5.966-971.1984
   PubMed Web of Science ®Google Scholar
• Darfeuille-Michaud A. Adherent-invasive Escherichia coli: a putative new E. coli pathotype associated with Crohn’s disease. Int J Med Microbiol. 2002;292(3–4):185–193. doi:10.1078/1438-4221-00201
   Web of Science ®Google Scholar
• Liu Y, Van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn’s disease. Gastroenterology. 1995;108(5):1396–1404. doi:10.1016/0016-5085(95)90687-8
   Web of Science ®Google Scholar
• Wakefield AJ, Ekbom A, Dhillon AP, Pittilo RM, Pounder RE. Crohn’s disease: pathogenesis and persistent measles virus infection. Gastroenterology. 1995;108(3):911–916. doi:10.1016/0016-5085(95)90467-0
   Web of Science ®Google Scholar
• Mitsuyama K, Niwa M, Takedatsu H, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304–1310. doi:10.3748/wjg.v22.i3.1304
   PubMed Web of Science ®Google Scholar
• Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232–1236. doi:10.1136/gut.2004.060228
   PubMed Web of Science ®Google Scholar
• van Schaik FD, Oldenburg B, Hart AR, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut. 2013;62:683–688. doi:10.1136/gutjnl-2012-302717
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn’s disease in children. Clin Gastroenterol Hepatol. 2008;6:1105–1111. doi:10.1016/j.cgh.2008.04.032
   PubMed Web of Science ®Google Scholar
• Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol. 2006;101:645–652. doi:10.1111/j.1572-0241.2006.00468.x
   PubMed Web of Science ®Google Scholar
• Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn’s disease. Gastroenterology. 2006;130:1069–1077. doi:10.1053/j.gastro.2006.02.003
   PubMed Web of Science ®Google Scholar
• Choung RS, Princen F, Stockfisch TP, et al. Serologic microbial associated markers can predict Crohn’s disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016;43:1300–1310. doi:10.1111/apt.13641
   PubMed Web of Science ®Google Scholar
• Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144–164K.
   PubMed Web of Science ®Google Scholar